Thousands could be saved by making this small change to heart failure treatment
New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according to the National Institute for Health and Care Excellence (Nice).
The draft guidelines recommend that medicines be administered up to a year earlier for a specific type of heart failure known as heart failure with reduced ejection fraction (HFrEF).
This condition occurs when the left side of the heart struggles to pump blood effectively throughout the body.
HFrEF affects approximately 387,000 of the 614,000 adults in England who suffer from heart failure. The new Nice guidelines aim to improve outcomes for these patients by ensuring timely and effective treatment.
Nice said medics are already changing practice to ensure that the four pillars of treatment – angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor – can be used earlier without the need to optimise the dose of any one medicine before introducing another.
Nice is recommending widespread earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozin – giving them at the start of treatment rather than waiting up to a year for dosage of other drugs to be optimised.
Generally, Nice said the drugs can also be started by GPs with advice from a heart failure specialist, rather than having to refer people to hospitals.
Eric Power, deputy director in Nice's centre for guidelines, said: 'Heart failure is common, with currently around 614,000 adults in England living with a diagnosis.
'Although there's no cure, it is treatable, and the growing number of people living with heart failure is testament to the improvements in care introduced over recent years.
'For this update we've been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments.
'This should have a big impact on the lives of people living with heart failure as well as freeing up space in hospitals by reducing their risk of having to go to hospital for unplanned emergency treatment.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
UK Pharmaceutical industry at risk from government's 'sky-high' rebates system
The UK's status as a leader in medical research is at risk from 'sky-high and unpredictable' repayments pharmaceutical firms hand the Government, says an industry boss. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said the rebate system – where firms repay money they make through selling medicines to the NHS – was sending 'a terrible message to international investors'. Rachel Reeves promised to support 'the UK's strengths in life sciences' and 'ensure patients get rapid access to the most clinically and cost-effective new technologies'. The Treasury plans to invest up to £520million in drug manufacturing in the next five years. Another £600million is earmarked for a health data research service to accelerate the discovery of new medicines. But Torbett said more was needed. 'Over the past decade, accounting for inflation, the NHS budget has grown by a third in real terms, while investment in the most rigorously cost-benefit-tested part of health spending – investment in the medicines needed to treat people – has fallen from around 11 per cent to 9 per cent of the health budget,' he added. And he attacked plans to increase what drug companies must repay from drug sales to 31.3 per cent, from 15.5 per cent. 'The sky-high and unpredictable payment rates send a terrible message to international investors when the UK is trying to position life sciences research and development as an engine for health and growth. For the sake of patients, the NHS and the economy, we need a commitment to bring these unsustainable rates down.'
Reuters
an hour ago
- Reuters
US health chief Kennedy names new members to vaccine advisory committee
WASHINGTON, June 11 (Reuters) - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday announced new members to the U.S. Centers for Disease Control and Prevention panel of vaccine experts, days after he said he fired all 17 of its members. The new members are: Joseph R. Hibbeln, Martin Kulldorff, Retsef Levi, Robert W. Malone, Cody Meissner, James Pagano, Vicky Pebsworth and Michael A. Ross. "All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense," Kennedy said in a post on X.
The Independent
an hour ago
- The Independent
The Inkey List's glycolic acid exfoliating stick worked magic on my keratosis pilaris
If you struggle with keratosis pilaris (also known as strawberry skin – a build-up of keratin within our skin pores) or sore razor bumps, then listen up. The much loved-affordable skincare brand The Inkey List may have produced the answer to our collective grumbles. Having sold out after its original launch, this stick claims to reduce the appearance of keratosis pilaris, razor bumps, hyper-pigmentation, breakouts and ingrown hairs. Results are promised after just one week, and drastic improvements are said to be visible after a month of consistent use. How does this miracle product work? Well, it's a combination of skin-loving hero ingredients. The glycolic acid is used to exfoliate the skin's surface and remove dead cells that leave the skin feeling rough, bumpy and uneven in tone. Salicylic acid helps to unclog oily pores, which is what causes issues like breakouts and ingrown hairs. Finally, shea butter offers a hydrating and moisturising effect. Chemical exfoliants have become the way of the future, and after testing this product, I'm beginning to see why. Here's how I got on with this miracle stick. How I tested Using the exfoliating stick every night for the last two months, I targeted keratosis pilaris on my arm, as well as underarm razor bumps and dry heels and elbows. I followed instructions carefully, starting by only using the stick two or three times a week and building up to every night once my skin had gotten used to it. To assess the product's efficacy, I looked for two things, appearance and texture. I noted any decrease in redness and improvement in brightness and paid close attention to any changes in the dryness or bumpiness of my skin.
